Pharmaceutical company Johnson & Johnson (J&J) announced Wednesday that the booster dose of its Covid-19 vaccine has produced promising results in an initial study.
In a statement, the company explained that study participants who received the booster dose produced an antibody level 9 times higher than that seen 28 days after the first dose.
J & J’s global head of research and development, Mathai Mammen, explained that the one-dose schedule of the vaccine produces a long-lasting immune response for eight months, also according to initial data.
“With these new data, we also see that a booster dose … further increases antibody responses among study participants who had previously received our vaccine,” he added.
Mammen said the firm hopes to discuss with health authorities the possibility of boosting eight months or more after the primary one-dose vaccine.
J&J noted that significant increases in antibody levels were seen in participants between the ages of 18 and 55, and also in those older than 65 who received a lower booster dose.
The promising data, from a phase 1/2 trial, have not yet undergone a peer review, but their abstracts were sent to the journal on Tuesday. medRxiv for this purpose, the company added.
J&J did not mention the potential impact of this booster dose on the delta variant, although it assured that it generated a promising protection against it when disclosing that its duration reached eight months.